(Q35854811)

10 August 2017

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib (English)

1 reference

10 August 2017

1 reference

C Cauchi

1

1 reference

10 August 2017

N Somaiah

2

1 reference

10 August 2017

P F Engstrom

3

1 reference

10 August 2017

S Litwin

4

1 reference

10 August 2017

M Lopez

5

1 reference

10 August 2017

J Lee

6

1 reference

10 August 2017

M Davey

7

1 reference

10 August 2017

B Bove

8

1 reference

10 August 2017

M von Mehren

9

1 reference

10 August 2017

language of work or name

1 reference

27 November 2011

1 reference

Cancer Chemotherapy and Pharmacology

10 August 2017

1 reference

10 August 2017

69

1 reference

10 August 2017

4

1 reference

10 August 2017

977-982

1 reference

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313017

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313017

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313017

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313017

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313017

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313017

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

11 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-011-1785-7

Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313017

Early stopping designs based on progression-free survival at an early time point in the initial cohort

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22119758

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-011-1785-7

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22119758

1 reference